All In Biotech

Drug Trial Radar · NCT02619630

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients

Last checked: Nov 20, 2026Latest source record: Oct 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

275

Planned (sponsor's estimate)

Start

Dec 2015

Primary completion

Dec 2020

Study completion Dec 2025

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of nelarabine-based consolidation and maintenance therapy in term of relapse-free survival (RFS) in high-risk (HR) patients.

Conditions

  • T-cell Adult Acute Lymphoblastic Leukemia

Interventions

  • nelarabineDrug

    Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil \>1 Giga/Liter for a maximum of 5 blocks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival (DFS)Time frame: 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hematology

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.